Ken Griffin Xtant Medical Holdings, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Xtant Medical Holdings, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 79,356 shares of XTNT stock, worth $29,361. This represents 0.0% of its overall portfolio holdings.

Number of Shares

79,356

Previous 75,447 5.18%

Holding current value

$29,361

Previous $47,000 12.77%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.55 - $0.8 $2,149 - $3,127	3,909 Added 5.18%	79,356 $53,000
Q2 2024 Aug 14, 2024	BUY	$0.63 - $1.03 $6,296 - $10,293	9,994 Added 15.27%	75,447 $47,000
Q1 2024 May 15, 2024	BUY	$0.92 - $1.28 $5,140 - $7,151	5,587 Added 9.33%	65,453 $76,000
Q4 2023 Feb 14, 2024	BUY	$1.04 - $1.39 $29,229 - $39,065	28,105 Added 88.49%	59,866 $67,000
Q3 2023 Nov 14, 2023	BUY	$0.78 - $1.35 $3,628 - $6,280	4,652 Added 17.16%	31,761 $34,000
Q2 2023 Aug 14, 2023	BUY	$0.58 - $0.93 $2,671 - $4,283	4,606 Added 20.47%	27,109 $25,000
Q1 2023 May 15, 2023	SELL	$0.59 - $1.18 $12,481 - $24,962	-21,155 Reduced 48.46%	22,503 $14,000
Q4 2022 Feb 14, 2023	BUY	$0.5 - $0.8 $21,829 - $34,926	43,658 New	43,658 $28,000
Q3 2021 Nov 15, 2021	SELL	$1.05 - $2.0 $38,357 - $73,062	-36,531 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$1.38 - $2.46 $76,509 - $136,387	-55,442 Reduced 60.28%	36,531 $59,000
Q1 2021 May 17, 2021	BUY	$1.23 - $4.33 $30,647 - $107,890	24,917 Added 37.16%	91,973 $217,000
Q4 2020 Feb 16, 2021	BUY	$0.82 - $1.63 $54,985 - $109,301	67,056 New	67,056 $80,000

Others Institutions Holding XTNT

# of Institutions

Shares Held

98.2M

Call Options Held

Put Options Held

View Full List

About Xtant Medical Holdings, Inc.

Ticker XTNT
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 108,226,000
Market Cap $40M
Description
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healin...

More about XTNT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account